Citations

Clear

3641 citation(s) found for "South, S M".

Early Treatment Failure in Patients With Relapsed/Refractory Multiple Myeloma Receiving Bispecific T-Cell Engagers: Development and Validation of the CHARGE Prognostic Index
Zanwar, Saurabh S , Hansen, Doris K , Tan, Carlyn R , Peres, Lauren C , Popat, Rakesh , Afrough, Aimaz , Asoori, Sireesha , Dave, Mrugakshi , Portuguese, Andrew J , Kastritis, Efstathios , Davis, James A , Martinez-Lopez, Joaquin , Sborov, Douglas W , Mihalyova, Jana , Bal, Susan , Janakiram, Murali , Ferreri, Christopher , Biran, Noa , Herr, Megan M. , Grajales-Cruz, Ariel F , Khouri, Jack , Castaneda Puglianini, Omar , Liang, Emily C , Zolotov, Eli , Galarza Fortuna, Gliceida M , Julian, Kelley L , Sannareddy, Aishwarya , Anderson, Larry D , Raza, Shahzad , Dima, Danai , Anwer, Faiz , Kumar, Shaji K , Usmani, Saad , Huang, Chiung-Yu , Mian, Hira , Sidana, Surbhi , Patel, Krina , Lin, Yi , Costa, Luciano J

Mayo Clinic

Journal of Clinical Oncology | November 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/jco-26-01039 | PMID 43024836 Get It

Purpose Outcomes with bispecific T-cell engagers (TCEs) in relapsed/refractory multiple myeloma (RRMM) are heterogeneous. A practical tool to guide prognosis is needed. We developed a model integrating clinical, biological, and treatment-related variables to predict progression-free survival (PFS) in patients receiving B-cell maturation antigen (BCMA)- or G-protein–coupled receptor class 5 member D-directed TCEs. Methods We evaluated outcomes of 577 BCMA-directed and 366 talquetamab treatments across 15 US Multiple Myeloma Immunotherapy Consortium centers. Variables significantly associated with inferior PFS in a multivariate Cox model were incorporated into a prognostic score and validated in an independent multicenter International Myeloma Foundation cohort. Results With a median follow-up of 8.4 months, the median PFS was 6.4 months (7.0 months for BCMA TCE; 6.1 months for talquetamab); 92% of patients were triple-class-refractory. Six variables significantly associated with inferior PFS—high-risk cytogenetic abnormalities (HRCAs) [del(17p) or ≥2 HRCAs], hyperferritinemia (≥600 ng/mL), anemia (hemoglobin <9 g/dL), early relapse (<18 months from frontline therapy), general performance status (Eastern Cooperative Oncology Group Performance Status ≥2), and exposure to prior BCMA-directed therapy—were combined to form the CHARGE index, stratifying patients into three risk groups. The median PFS was 21.8 months (95% CI, 11.7 to not reached), 7.1 months (95% CI, 6.1 to 10.1), and 1.6 months (95% CI, 1.2 to 2.5) in the low-, intermediate-, and high-risk groups, respectively; hazard ratios (HRs) were 2.0 (95% CI, 1.5 to 2.7) and 4.8 (95% CI, 3.5 to 6.7) for intermediate- and high-risk versus low-risk groups. External validation (n = 173) showed that the median PFS was not reached, 7.0 months, and 3.0 months, with corresponding HRs of 2.9 (95% CI, 1.7 to 4.9) and 4.8 (95% CI, 2.6 to 8.7). Conclusion The CHARGE index provides a simplified and externally validated framework for predicting treatment outcomes in patients with RRMM receiving TCEs.
Predictors of learning the memory support system in individuals with amnestic mild cognitive impairment
Koay, Jun Min , Grant, Jeremy G , Aghamoosa, Stephanie , Shandera-Ochsner, Anne L, Chandler, Melanie J

Mayo Clinic

Journal of Clinical and Experimental Neuropsychology | November 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-9

10.1080/13803395.2026.2762996 | PMID 43018120 Get It

A translational platform for brain-computer interfaces and adaptive neuromodulation: Technical characterization, long-term validation, and implementation of the CorTec brain interchange-BCI2000 ecosystem
Lampert, Frederik , Baker, Matthew R , Engelhardt, William , Gkogkidis, C Alexis , Ayyoubi, Amir Hossein , Fazli Besheli, Behrang , Boom, Max van den , Kellar, Douglas J , Kim, Inyong , Staff, Nathan P , Schalk, Gerwin , Ince, Nuri Firat

Mayo Clinic

Journal of Neural Engineering | November 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1088/1741-2552/aec198 | PMID 43019594 Get It

Abstract Objective: Adaptive neuromodulation systems and implantable brain-computer interfaces (BCIs) are promising therapies for neurological and psychiatric disorders. However, their broader translation into research and clinical practice remains limited by technological complexity, restricted access to implantable research platforms, and the lack of standardized, reproducible experimental workflows. We therefore aimed to develop and validate an open, general-purpose translational ecosystem that enables rapid development, evaluation, and dissemination of novel neuromodulation and implantable BCI paradigms.&#xD;Approach: The CorTec Brain Interchange (BIC) implantable neural sensing and stimulation device was integrated with the open-source BCI2000 platform to create a modular, extensible neuromodulation ecosystem. We established a standardized battery of quantitative assessments to characterize implantable neuromodulation systems to comprehensively evaluate the CorTec BIC device through benchtop characterization, long-term preclinical in vivo validation, and a human feasibility demonstration using the benchtop BIC system connected to externalized leads.&#xD;Results: Comprehensive benchtop characterization of the BIC device independently validated previously reported performance while extending its evaluation through quantification of recording noise, acquisition and stimulation latencies, and validation of impedance measurements. Long-term in vivo validation in five canines, with the longest implantation exceeding three years, demonstrated stable chronic recordings while also capturing progressive deterioration of individual channels through longitudinal changes in signal quality and impedance. The ecosystem enabled active functional decoding more than two years after implantation, closed-loop stimulation using arbitrary spectral biomarkers, capturing brain stimulation evoked potentials, detection of epilepsy-associated biomarkers and observational assessment of their response to stimulation. In addition, we translated an established one-dimensional BCI cursor-control paradigm to the BIC benchtop system, demonstrating ecosystem portability and feasibility with a human participant. Finally, we share surgical protocols, imaging and analysis pipelines, datasets, and software to facilitate reproducible neuromodulation research.&#xD;Significance: We present a versatile, open-source translational ecosystem that supports a wide range of neuromodulation and implantable BCI applications with minimal modification. By combining comprehensive hardware characterization with standardized software tools and experimental workflows, this work provides a practical reference for researchers adopting the BIC platform while establishing a broadly applicable framework for systematic characterization of implantable neuromodulation systems. The ecosystem lowers technical barriers to implantable neurotechnology research, promotes reproducibility, and provides a foundation for accelerating the development and clinical translation of next-generation adaptive neuromodulation and implantable BCI therapies for patients with neurological and psychiatric disorders.
Penicillin Allergy Delabeling in Children
Larson, Anthony S. , Lim, Peter Paul , Angal, Jyoti , Perry, Tamara T. , Blumenthal, Kimberly G.

Mayo Clinic

Pediatrics | November 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1542/peds.2026-077964 | PMID 42976931 Get It

Nearly 10% of the global population has been labeled as having a penicillin allergy. Of those labeled, about 95% are not truly allergic, yet most do not receive any allergy evaluations. Patients with penicillin allergy labels are more likely to have worse clinical outcomes and incur higher health care costs, largely because they do not receive penicillin and other first-line β-lactam antibiotics for the treatment of infectious diseases. Consequently, the process of evaluating and removing inaccurate penicillin allergy labels—a process known as “delabeling”—has become increasingly supported by a growing body of evidence. Recently, penicillin allergy has garnered substantial public interest with the proposal of federal legislation to include evaluation of penicillin allergy during routine medical visits for Medicare patients. Although this moves delabeling into the generalist purview, most of the emphasis on penicillin allergies and delabeling has been on adult patients. Yet, penicillin allergy is a pressing issue for pediatrics, as most penicillin allergy labels are placed in childhood. Pediatric literature similarly demonstrates negative clinical and public health consequences of inaccurate penicillin allergy labels. Recent guidelines have strongly recommended a proactive effort to identify and delabel inaccurate penicillin allergies in children. To facilitate this process, simple delabeling procedures, such as direct oral challenge with amoxicillin, have been recommended for patients with low-risk allergy status, based on historical reaction verification, because of their safety and accuracy. These advancements are relevant to practicing pediatricians across specialties and practice locations.
The hearing healthcare workforce: insights into density, distribution and opportunities for capacity-development
Mokoh, Lilian , Law, Shen Hong , Jaffer, Ali F. , Seguya, Amina , Kahinga, Aveline Aloyce , Nakku, Doreen , Holt, Elizabeth A.L. , Dillard, Lauren K. , Zalaquett, Nader , Frost, Robert, Patterson, Rolvix H. , Nuss, Sarah , Xu, Mary Jue , Elwell, Zachary , Waterworth, Christopher J.

Mayo Clinic

International Journal of Audiology | October 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-13

10.1080/14992027.2026.2738096 | PMID 42860054 Get It

Left Atrial Appendage Occlusion vs Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation: A Meta‐Analysis
Nazmy, Ahmed , Abouelmagd, Alaa Abdrabou , Sobhy, Ahmed , Ashour, Mennatullah , El‐shirbiny, Hassan , Khalaph, Moneeb , Shaban, Ahmed Yasser , Nazmy, Mahmoud , Shabaan, Amroos , Elbanna, Abdullah Farahat, Hafez, Abdelrahman , Gibson, C. Michael

Mayo Clinic

Pacing and Clinical Electrophysiology | October 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/pace.70465 | PMID 42855979 Get It

ABSTRACT Background Left atrial appendage occlusion (LAAO) has emerged as a non‐pharmacological alternative to oral anticoagulation (OAC) for stroke prevention in patients with atrial fibrillation (AF). Following the publication of recent CHAMPION‐AF and CLOSURE‐AF trials, an updated synthesis of evidence is warranted to clarify the long‐term comparative efficacy and safety of LAAO versus OAC in patients with AF. Methods We conducted a systematic review and meta‐analysis of randomized controlled trials (RCTs) comparing LAAO with OAC in adults with AF. A comprehensive search of major databases was performed from inception to April 2026. The primary efficacy outcomes were major adverse cardiovascular events (MACE) and stroke. The primary safety outcome was non–procedure‐related bleeding. Random‐effects models were used to calculate pooled risk ratios (RRs) with 95% confidence intervals (CIs). Results Six RCTs including 7,004 patients (3,681 LAAO; 3,323 OAC) were analyzed. No statistically significant difference was observed for MACE (7.5% vs 6.9%; RR 1.03, 95% CI 0.79‐1.34) or stroke (3.7% vs 3.2%; RR 1.07, 95% CI 0.80‐1.43). LAAO was associated with a significantly lower risk of non‐procedure‐related bleeding (9.8% vs 16.7%; RR 0.63, 95% CI 0.52‐0.77), corresponding to an absolute risk reduction of 6.9% and an approximate number needed to treat of 15 based on crude pooled event rates over the observed trial follow‐up. Trial sequential analysis indicated that the accumulated evidence for MACE and stroke remained inconclusive. Comparator‐type subgroup analyses showed no significant interaction for MACE ( p = 0.67) or stroke ( p = 0.81) between contemporary predominantly‐DOAC and VKA comparator trials. Conclusions LAAO was associated with lower non‐procedure‐related bleeding, while no statistically significant differences were observed for MACE or stroke. The available efficacy evidence remains inconclusive regarding equivalence or non‐inferiority, and larger trials are needed. These findings support individualized consideration of LAAO when the long‐term bleeding burden of anticoagulation is clinically important.
PDS0101 With Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Weiss, J., Chintakuntlawar, Ashish, Worden, Francis P., Mehra, Ranee , Kang, Hyunseok , Zinner, Ralph G., Arnold, Susanne M. , Bhateja, Priyanka, Harrington, Kevin, Gupta, Shilpi, Zhao, Yujie, Pham, Dahn C., Najeeb, Sidra, Kaur, Varinder, Sukari, Ammar, Giri, Anshu , Panella, Timothy J., Grewal, Jaspreet, Galligan, Barbara, Nadler, Eric, Grant, Cliona, Arteta-Bulos, Rafael, Schaaf, David, Price, Katharine A., Kang, Hyunseok , Weiss, Jared, Kaczmar, John M. , Zinner, Ralph , Harrington, Kevin J. , Kaur, Varinder , Sukari, Ammar , Panella, Timothy, Grewal, Jaspreet Singh , Galligan, Barbara Marie, Nadler, Eric , Noble, David J. , Schaaf, David

Mayo Clinic

JAMA Oncology | September 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamaoncol.2026.3492 | PMID 42752531 Get It

Importance The incidence of human papillomavirus type 16 (HPV16–positive) recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) is rising. Approved therapies offer a durable response to a minority of patients. Objective To determine the efficacy and safety of a therapeutic HPV16-targeted immunotherapy, PDS0101, in combination with pembrolizumab in participants with HPV16-positive R/M HNSCC, with separate evaluation of immune checkpoint inhibitor (ICI)–naive and ICI-resistant cohorts. Design, Setting, and Participants VERSATILE-002 was a phase 2, open-label, multicenter nonrandomized clinical trial conducted at 26 oncology centers from March 29, 2021, to May 15, 2025, across the US, UK, and Ireland using the Simon 2-stage optimal design. Efficacy analyses were performed on modified intent-to-treat (mITT) population; safety analyses included all participants who received 1 or more doses. Eighty-eight participants with histologically confirmed R/M HPV16-positive HNSCC were enrolled, of whom 87 (98.9%) received treatment and composed the safety population. Seventy five (85.2%) were in the mITT population used for efficacy analyses, of whom 53 (70.7%) were ICI-naive with a programmed cell death ligand 1 combined positive score of 1 or greater and 22 (29.3%) were ICI-resistant. Exposures Pembrolizumab (200 mg, intravenously, every 3 weeks for up to 35 cycles) plus subcutaneous PDS0101 (5 scheduled doses per protocol). Main Outcomes and Measures The primary end point was objective response rate (ORR) per the Response Evaluation Criteria in Solid Tumors , version 1.1, by a masked independent central reviewer. Secondary end points included progression-free survival (PFS), median overall survival (mOS), and safety, with exploratory end points of duration of response, disease control rate, and response rates by programmed cell death ligand 1 status. Results Of the 75 patients in the mITT population, the mean (SD) age was 64.0 (8.3) years; 4 individuals (5%) were female and 71 (95%) were male; and 2 individuals (3%) were Asian, 1 (1%) was Black, 5 (7%) were Hispanic, and 71 (95%) were White. Among 53 ICI-naive participants in the mITT cohort, ORR by the central reviewer was 34.0%, median PFS was 5.3 months (95% CI, 2.10-9.00), and mOS was 39.3 months (95% CI, 23.90 to not evaluable). Among 22 ICI-resistant patients in the mITT cohort, no objective responses were observed and the primary end point (ORR by central reviewer) was not met, but mOS was 14.8 months (95% CI, 8.50-26.00). The treatment was well tolerated, with 13.8% experiencing grade 3 or higher treatment-related adverse events. Conclusions and Relevance The results of this nonrandomized clinical trial suggest that PDS0101 plus pembrolizumab showed antitumor activity in ICI-naive HPV16-positive R/M HNSCC, with favorable safety, response rates, and survival outcomes. The findings support further evaluation in a first-line setting. Trial Registration ClinicalTrials.gov Identifier: NCT04260126
Effect of Thrombus Composition on Functional Outcomes After Ischemic Stroke Therapy: A GRADE-Assessed Systematic Review and Meta-Analysis
Hamza, Ahmad, Harb, Ahmed , Mosad, Nada , Nasreldin, Asmaa , Abbas, Omar F. , Lara-Velazquez, Montserrat , Tsehaye, Eseyas, Reda, Abdullah, Ghozy, Sherief, Brinjikji, Waleed, Kallmes, David, Quadir, Mohiuddin , Kadirvel, Ram, Lara‐Velazquez, Montserrat , Tsehaye, Eseyas Semere, Hamouda, Abdelrahman M. , Reda, Abdullah, Ghozy, Sherief , Brinjikji, Waleed , Kadirvel, Ramanathan

Mayo Clinic

Asian Journal of Neurosurgery | September 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0046-1829092 Get It

Abstract Stroke thrombi are heterogeneous; their composition influences their mechanical properties, including stiffness, elasticity, and adhesiveness, which in turn affect their response to therapy. Systemic characterization of the thrombi components could help select therapeutic techniques and anticipate outcomes. We conducted a systematic review and meta-analysis to evaluate associations between thrombi composition and angiographic and functional outcomes in acute ischemic stroke (AIS). Up to May 2025, relevant studies were sourced from four databases: PubMed, Web of Science, Scopus, and Embase. We included cohort studies whose populations are patients with AIS in relation to thrombi composition. Thirty-six studies involving 5,462 patients matched our eligibility criteria. Angiographic success (Thrombolysis in Cerebral Infarction ≥ 2b/3) did not differ significantly between red blood cell (RBC)-rich and fibrin-rich thrombi (risk ratio [RR] 1.02, 95% confidence interval [CI] 0.85–1.22; p = 0.84; I 2 = 63.8%; very low certainty). However, thrombi from patients with good angiographic outcomes had a significantly higher RBC content compared to patients with poor outcomes (mean difference = 7.22%, 95% CI 3.31–11.13; p < 0.001; low certainty). No significant difference was observed between RBC-rich and fibrin-rich thrombi regarding functional independence at 90 days (modified Rankin Scale 0–2) (RR = 1.22, 95% CI 0.73–2.05; p = 0.31; low certainty). While RBC-rich thrombi are associated with more favorable angiographic performance, thrombus composition alone does not predict functional outcomes. Stroke outcomes remain multifactorial, dominated by time to reperfusion, collateral circulation, and baseline severity. Preinterventional assessment of clot composition via imaging or biomarkers may support individualized therapy but should complement, not replace, other prognostic determinants.
Revascularization in Asymptomatic Carotid Artery Stenosis With Hemodynamic Impairment and Cognitive Outcomes
Marshall, Randolph S. , Lazar, Ronald M. , Meschia, James F., Huston, John, Edwards, Lloyd J., Brott, Thomas G., Lal, Brajesh K., Howard, George, Mena-Hurtado, Carlos, Heck, Donald, Sangha, Navdeep, Lanzino, Giuseppe, Kashyap, Vikram S. , Aronow, Herbert D. , Sharafuddin, Mel, Voeks, Jenifer, Slane, Kevin, Liebeskind, David S., Meschia, James F. , Edwards, Lloyd J. , Brott, Thomas G. , Lal, Brajesh K. , Mena‐Hurtado, Carlos , Heck, Donald , Sangha, Navdeep , Lanzino, Giuseppe , Voeks, Jenifer H. , Zhang, Yu , Slane, Kevin, Liebeskind, David S.

Mayo Clinic

JAMA | September 16, 2026 | Volume: 336 | Issue: 16 | Pages: 1416

10.1001/jama.2026.13384 | PMID 42747834 Get It

Importance Cerebral hemodynamic impairment in patients with asymptomatic internal carotid artery (ICA) stenosis is associated with reduced cognition. It is uncertain whether revascularization might be an effective treatment for cognitive impairment in these patients. Objective To test whether any cognitive benefit from revascularization of high-grade, asymptomatic ICA stenosis varies based on the degree of baseline cerebral hemodynamic impairment. Design, Setting, and Participants This substudy was conducted within a multicenter phase 3 randomized clinical trial. Adults (aged 35-86 years) without dementia with eighth-grade education or higher and unilateral asymptomatic ICA stenosis greater than or equal to 70% were enrolled from January 2018 to July 2024 at 61 sites in North America (last follow-up in July 2025). Of 607 participants screened from 2485 in CREST-2, 392 were enrolled. Magnetic resonance or computed tomographic perfusion imaging tested for baseline hemodynamic impairment defined by delayed time-to-peak (TTP) arrival of intravenous contrast in the hemisphere ipsilateral minus contralateral to the stenotic artery. Intervention Carotid revascularization (endarterectomy or stenting) plus intensive medical management (IMM) vs IMM alone. Main Outcomes and Measures The primary outcome was the difference in composite cognitive z score over 1 year based on 5 cognitive tests. The primary analysis tested for an interaction between treatment group (revascularization vs IMM alone) and degree of baseline hemodynamic impairment among those with reduced baseline cognition (cognitive z score ≤−1.0 SD). Results Of 392 participants enrolled (mean age, 71 years; 125 [32%] females), 61 were excluded for missing baseline imaging and 40 for missing cognitive examinations or other covariates, leaving 291 with complete data. Fifty-one had reduced cognition at baseline (25 in the revascularization group and 26 in the IMM alone group). TTP ranged from no interhemispheric TTP delay to a more-than-2-second delay. Mean (SD) cognitive z scores were −1.36 (0.51) at baseline and −1.17 (0.47) at 1 year in the revascularization group and −1.34 (0.83) at baseline and −1.01 (0.97) at 1 year in the IMM alone group. The primary analysis showed no difference in cognition by treatment group over 1 year, adjusting for treatment group × hemodynamic status interaction and other covariates (adjusted difference in cognitive z score, −0.15 SD [95% CI, −0.54 to 0.24]). The interaction was not significant (β estimate = 0.018 [95% CI, −0.025 to 0.061]; P = .40). Conclusions and Relevance In this substudy of a randomized clinical trial, there was no differential effect of revascularization vs IMM alone on cognition over 1 year by cerebral hemodynamic status among those with baseline reduced cognition, suggesting that revascularization does not improve cognitive dysfunction by restoring flow to the brain in chronic asymptomatic carotid stenosis. Trial Registration ClinicalTrials.gov Identifier: NCT03121209
Periodontitis, Tooth Loss, and Risk of Cognitive Impairment and Dementia: A Systematic Review With Meta‐Analysis
Sen, Souvik , Zhou, Miao Xian , Slashcheva, Lyubov , Demmer, Ryan T , Watson, Dave , Goh, Charlene E , Slashcheva, Lyubov D , Zhou, Miao Xian , Kebschull, Moritz , Sen, Souvik , Noble, James M , Papapanou, Panos N , Demmer, Ryan T. , Watson, David , Goh, Charlene Enhui , Tom, Sarah E. , Noble, James M.

Mayo Clinic

Journal of Periodontal Research | September 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/jre.70177 | PMID 42747062 Get It

ABSTRACT Aim To systematically review and meta‐analyze cohort studies evaluating associations of gingival inflammation, periodontitis, and tooth loss with cognitive decline and incident mild cognitive impairment or dementia. Methods PROSPERO‐registered searches of MEDLINE, Embase, Scopus, Web of Science, and the Cochrane Library identified cohort studies from inception through October 10, 2025, with a PubMed update on June 24, 2026. Random‐effects meta‐analyses pooled adjusted hazard ratios (HRs) for dementia/MCI; cognitive function outcomes were summarized qualitatively. Risk of bias (RoB) was assessed using the Newcastle–Ottawa Scale. Results Fifty‐nine studies met inclusion criteria; 28 contributed to dementia/MCI meta‐analyses. Severe periodontitis (HR: 1.16; 95% CI: 1.06–1.27; I 2 = 0%; Q ‐test p = 0.49), periodontitis of unspecified severity (HR: 1.45; 95% CI: 1.21–1.73; I 2 = 98%; Q ‐test p < 0.001), edentulism (HR: 1.26; 95% CI: 1.19–1.33), and low tooth count (HR: 1.27; 95% CI: 1.14–1.42; I 2 = 94%; Q ‐test p < 0.001) were associated with elevated dementia/MCI risk. RoB was low in 31 studies (53%), moderate in 25 (42%), and high in 3 (5%); inadequate confounder adjustment was common. Meta‐regression showed stronger estimates for ICD‐code periodontitis definitions (fold change (FC) = 1.44 95% CI: 1.04–2.01), older cohorts (FC per year = 1.02 95% CI: 1.00, 1.05), and weaker estimates with lower RoB (FC per NOS star = 0.81 95% CI: 0.73–0.92). Follow‐up duration, cohort age, and RoB were not associated with tooth‐count estimates. Conclusion Periodontitis and tooth loss are associated with modestly higher dementia/MCI risk and poorer cognitive function, but heterogeneity, residual confounding, and bias temper causal interpretation. Longitudinal studies with rigorous baseline cognition assessment and intervention studies are needed.